As of March 23, 2026, Nurix Therapeutics's top three insider holders are Group L P Column (TenPercentOwner, 1.44Mn shares), Gwenn Hansen (Chief Scientific Officer, 115.00K shares), Houte Hans Van (Chief Financial Officer, 45.43K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Group L P Column | 1,394,333 | 48,406 | 07 May, 2021 | |
| Gwenn Hansen | Chief Scientific Officer | 115,005 | 0 | 03 Feb, 2026 |
| Houte Hans Van | Chief Financial Officer | 45,427 | 0 | 30 Jan, 2026 |
| Christine Ring | Chief Legal Officer | 34,601 | 0 | 02 Mar, 2026 |
| Stefani Wolff | Evp And Coo | 6,113 | 0 | 02 May, 2023 |
| Pierre Beaurang | Chief Business Officer | 4,330 | 0 | 11 Aug, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Mar, 2026 | Christine Ring | Common Stock | D | 8,148 | $15.44 | 34,601 | D | S |
| 10 Feb, 2026 | Arthur T Sands | Employee Stock Option (right to buy) | A | 562,500 | $0.00 | 562,500 | D | A |
| 10 Feb, 2026 | Gwenn Hansen | Employee Stock Option (right to buy) | A | 93,750 | $0.00 | 93,750 | D | A |
| 10 Feb, 2026 | Christine Ring | Employee Stock Option (right to buy) | A | 93,750 | $0.00 | 93,750 | D | A |
| 10 Feb, 2026 | Houte Hans Van | Employee Stock Option (right to buy) | A | 93,750 | $0.00 | 93,750 | D | A |
| 10 Feb, 2026 | Houte Hans Van | Restricted Stock Units | A | 42,875 | $0.00 | 42,875 | D | A |
| 10 Feb, 2026 | Gwenn Hansen | Restricted Stock Units | A | 42,875 | $0.00 | 42,875 | D | A |
| 10 Feb, 2026 | Christine Ring | Restricted Stock Units | A | 42,875 | $0.00 | 42,875 | D | A |
| 09 Feb, 2026 | Christine Ring | Common Stock | D | 14,261 | $16.66 | 42,749 | D | S |
| 03 Feb, 2026 | Gwenn Hansen | Common Stock | A | 31,333 | $0.84 | 115,005 | D | M |
| 03 Feb, 2026 | Gwenn Hansen | Employee Stock Option (right to buy) | D | 31,333 | $0.00 | 0 | D | M |
| 30 Jan, 2026 | Christine Ring | Common Stock | A | 1,925 | $0.00 | 52,822 | D | M |
| 30 Jan, 2026 | Houte Hans Van | Common Stock | A | 2,887 | $0.00 | 40,479 | D | M |
| 30 Jan, 2026 | Gwenn Hansen | Common Stock | A | 3,207 | $0.00 | 79,958 | D | M |
| 30 Jan, 2026 | Gwenn Hansen | Common Stock | A | 2,000 | $0.00 | 81,958 | D | M |
| 30 Jan, 2026 | Christine Ring | Common Stock | A | 2,000 | $0.00 | 54,822 | D | M |
| 30 Jan, 2026 | Houte Hans Van | Common Stock | A | 2,000 | $0.00 | 42,479 | D | M |
| 30 Jan, 2026 | Gwenn Hansen | Common Stock | A | 3,750 | $0.00 | 85,708 | D | M |
| 30 Jan, 2026 | Christine Ring | Common Stock | A | 3,750 | $0.00 | 58,572 | D | M |
| 30 Jan, 2026 | Houte Hans Van | Common Stock | A | 3,750 | $0.00 | 46,229 | D | M |